SecBot SecBot
PRESS-RELEASE ·Filed Mar 31, 2026

BIIB

Biogen Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The acquisition provides immediate revenue and strategic expansion into nephrology and retinal disease, with strong growth visibility. Traders should monitor SYFOVRE® sales trajectory and upcoming FDA submission for prefilled syringe in H1 2026, which could accelerate adoption. The CVR structure aligns incentives and limits near-term dilution, while Biogen’s plan to de-lever by 2027 supports financial stability.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$182.52
T+0 close · Mar 31, 2026 · via day close
Latest settled
+10.65%
T+60 · $201.96
Vs SPY
−2.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $182.52entry
  2. T+1 · 8mo ago +0.31%α −0.44% · $183.08
  3. T+5 · 7mo ago −1.43%α −5.38% · $179.90
  4. T+20 · 7mo ago +4.31%α −5.11% · $190.39
  5. T+60 · 5mo ago +10.65%α −2.26% · $201.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, totaling $5.6 billion in upfront equity consideration, plus a contingent value right (CVR) tied to SYFOVRE® sales milestones. The deal adds two FDA-approved complement-targeting therapies, EMPAVELI® and SYFOVRE®, with combined 2025 revenue of $689 million and expected mid-to-high teens growth through 2028, enhancing Biogen’s immunology and nephrology portfolio.

Key Financial Metrics

Revenue
$689.0M
Deal Value
$5.6B

Key Facts

  • Biogen to acquire Apellis for $41 per share in cash, representing an 86% premium to Apellis’s 90-day volume-weighted average price.
  • Total upfront equity value is $5.6 billion; additional CVR of up to $4 per share based on SYFOVRE® global net sales milestones ($1.5B and $2B thresholds between 2027–2030, or $2B in 2031).
  • EMPAVELI® and SYFOVRE® generated combined net revenue of $689 million in 2025, expected to grow at mid-to-high teens rate at least through 2028.
  • Transaction expected to be accretive to Biogen’s non-GAAP EPS starting in 2027 and boost its non-GAAP EPS CAGR through the end of the decade.
  • Deal expected to close in Q2 2026, financed via cash and borrowings; Biogen expects to de-lever fully by end of 2027.

Financial Impact

$5.6 billion upfront cash outlay with potential $4 per share CVR payout; adds $689 million in annual revenue with strong growth trajectory

revenueepsdebtdilution

Risk Factors

  • Failure to achieve SYFOVRE® sales milestones could result in no CVR payout, reducing deal upside.
  • Integration risk and potential disruption to Apellis’s commercial momentum in key rare disease markets.
  • Regulatory or antitrust delays could push closing beyond Q2 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
47% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3265288

Track record

34 reports on BIIB

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026